{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-176718","form_type":"8-K","ticker":"FDMT","cik":"0001650648","company_name":"4D Molecular Therapeutics, Inc.","filed_at":"2022-06-21T23:59:59+00:00","discovered_at":"2026-05-14T18:04:01.639954+00:00","generated_at":"2026-06-25T00:25:56.804461+00:00","sec_items":["5.03","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"confidence":"high","headline":"4D Molecular Therapeutics amends bylaws for universal proxy rules and exclusive federal forum for Securities Act claims","bullets":["Board amended bylaws on June 14, 2022 to incorporate universal proxy rules for director nominations.","Forum selection provision changed to make U.S. federal district courts exclusive for Securities Act claims.","Amended and restated bylaws filed as Exhibit 3.1 to the 8-K."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-176718","json":"https://secwatch.observer/filing/0001193125-22-176718.json","markdown":"https://secwatch.observer/filing/0001193125-22-176718.md","text":"https://secwatch.observer/filing/0001193125-22-176718.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1650648/000119312522176718/0001193125-22-176718-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1650648/000119312522176718/d277212d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T00:25:56.804461+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}